En esta entrevista, discutimos los siguientes temas: * Menos función cardiovascular * Hipertensión * La conexión entre el funcionamiento del corazón menos y el hipotiroidismo * El riesgo cardiovascular * Resistencia cardiovascular * Mayor colesterol LDL e hipotiroidismo * Hipotiroidismo subclínico y riesgo * Niveles de TSH * Niveles de TSH por encima de 10 * Colesterol e hipotiroidismo * Riesgo residual y estatinas * Mejorando la absorción de T4 * Levotiroxina y buen cumplimiento * Osteoporosis
In this episode, topics include: * Drug therapy for patients that fail standard therapy; including surgery and RAI * Not all patients have same behavior for their cancer * Some cancers are aggressive * Not many thyroid cancer patients are affected by this; maybe a few thousand in the U.S., but not tens of thousands * What is the treatment protocol for therapy? * Lenvatinib or Sorafenib is the treatment for refectory thyroid cancer * Lenvatinib tends to be more effective * Sorafenib is tolerated by the patient better * Other options to consider include, molecular profiling or some thyroid cancers carry mutation that is targetable, or BRAF * BRAF inhibitors used with thyroid cancer patients * Molecular profiling * DNA sequencing
Kimberly Vanderveen, MD is a Colorado native and graduate of Bear Creek High School in Lakewood, CO. She received her bachelor’s degree with honors from Muhlenberg College in Allentown, PA. She then earned her medical degree from Northwestern University in Chicago, IL in 2001. In this episode, the following topics are discussed: * Two roads of tests: rule out and malignant markers * Rule-out tests picks up innocent behavior pattern. Most common is Afirma * Malignant markers, or rule-in tests, are useful at determining extent of surgery, and help avoid a second or third surgery. ThyroSeq, ThyraMIR, Rosetta * Do patients get both tests? Rule out and behavior? * Approximately 15% of FNA’s come back indeterminate. Some centers as high as 30% * Managing indeterminate nodules when a patient chooses no surgery. * Taking into account emotional, financial, and lifestyle goals of the patient.
Bryan McIver, MD, PhD Dr. McIver contributes to Moffitt Cancer Center almost 20 years of clinical experience in the care of patients with endocrine diseases, specializing in the evaluation of patients with thyroid nodules and thyroid cancer. He has a particular interest in the management of patients with advanced and aggressive forms of cancer and the role of genetic and molecular techniques to improve the accuracy of diagnosis. Most nodules are benign When to do a biopsy How to interpret the results of biopsy Advances in thyroid cancer Ultrasound technology advancements Molecular markers Cytopathology categorizations Molecular marker technologies Gene expression classifier
In this interview, Dr. Kaptein discusses the need to consider each patient before making treatment decisions. In some cases, this may mean foregoing the removal of cancerous lymph nodes.
Carmelo Nucera, M.D., Ph.D., is currently an Assistant Professor at Harvard Medical School, Boston, in the Division of Cancer Biology and Angiogenesis (Department of Pathology), Beth Israel Deaconess Medical Center. Dr. Nucera received his M.D. and Ph.D. in Experimental Endocrinology and Metabolism from Italy. In this episode, Dr. Nucera discusses a combination drug therapy using vemurafenib and palbociclib represents a novel therapeutic strategy to treat papillary thyroid carcinoma (PTC).
In this episode, the following topics are explained: * Optimizing thyroid health prior to conception * Thyroid issues that affect pregnancy * Hypothyroid as result of surgery or Hashimotos * Hyperthyroidism and pregnancy * Adjusting current thyroid treatment, meaning optimizing thyroid levels by adjusting dosage of thyroid medication * TSH levels in light of pregnancy * Planned pregnancy usually means a dose increase
Dr. Paul Y. Casanova-Romero, M.D., M.P.H., F.A.C.P., F.A.C.E, E.C.N.U, que se unió a Palm Beach Diabetes y Endocrine Specialists en 2012, recibió su grado médico con honores (Summa Cum Laude) y Doctor en Ciencias Médicas (DMSc), de la Universidad de Zulia, la Escuela de Medicina en Venezuela. * ¿Cómo se identifican los nódulos y por qué ocurren? autoexamen o en la oficina del médico * La mayoría de los nódulos son benignos pero ocurren porque en mas de 70% de la población * ¿Qué tests puede realizar un médico para evaluar el nódulo? * Ninguna test es 100% * Ultrasonido - qué están buscando en general * Que es ojo fina y el proceso general * Tests moleculares * ¿Qué tipos de resultados se pueden obtener de la citología y qué significan? * La mayoria de ojo finas son benigno
* Imaging has increased thyroid nodule discovery. * Following patients with small thyroid cancer ? analogous to prostate cancer. Better followed than treated. * Tiny thyroid cancers can be defined by those nodules less than 1/4 inch in size. * Less RAI is being used as a part of thyroid cancer treatment. This means, less need to do total thyroidectomy or thyroid lobectomy. * Dry mouth and dry eyes are risks to doing RAI. Also, there is risk to developing a second malignancy. Most of the secondary cancers are leukemia. * Risks to operation include changes to voice and calcium levels. Thyroid surgery is a safe operation but not risk free. * Best question for a patient to ask is, who is my treatment team?
Thyroid surgery and RAI sometimes results in hypothyroidism Most common cause is Hashimoto’s disease Weight gain, dry skin, constipation Very few symptoms unique to hypothyroidism Sleep apnea and being tired all of the time and weight gain. Brain fog and difficulty concentrating Blood tests diagnose hypothyroidism based on TSH levels, when elevated means it is not working too well. Explaining TSH in laymen’s terms Normal TSH in the U.S. is .3 to 3.5 Treating for feel rather than a number People with elevated TSH have many of the hypothyroid symptoms, but people with normal TSH levels may also have hypothyroid symptoms